Search

• A series of new coumarino-azetidinones (3a-l) were designed and synthesized. • All the compounds were screened for antitubercular and antimicrobial activity. • Compounds 3e and 3k emerged out as promising antituberculars and antimicrobials. • Compounds 3e and 3k were exhibited comparatively less toxicity. • Excellent molecular docking scores were observed. In the present work, a series of new coumarino-azetidinones (3a-l) were designed, synthesized and evaluated for biological activities. The newly synthesized compounds (3a-l) were fully characterized by several spectroscopic techniques and elemental analyses. The synthesized compounds (3a-l) were screened for their preliminary in-vitro antitubercular and antimicrobial activities. Almost all the coumarino-azetidinones showed promising activity against Mycobacterium tuberculosis (M. tuberculosis) H 37 Rv strain. Conversely, some of the coumarino-azetidinones displayed interesting antimicrobial activities. Moreover, most active compounds were tested for cytotoxicity studies and exhibited low-level cytotoxicity towards Vero cells. Last but not the least, molecular docking results showed excellent interactions with M. tuberculosis InhA-D148G mutant (PDB. 4TZK) and Escherichia coli (E. coli) (PDB. 4JX8). The results of biological evaluation suggest that the coumarino-azetidinones are promising lead compounds for the subsequent investigation in search of new antitubercular and antimicrobial agents. Image, graphical abstract In the present study, a series of new coumarino-azetidinones were synthesized, characterized and evaluated for their preliminary antitubercular, antimicrobial and cytotoxicity activity. [ABSTRACT FROM AUTHOR]

• Novel coumarin-thioether conjugates were synthesised and characterised. • The synthesised compounds are assessed for in vitro anti-TB activity (H 37 Rv strain). • Compound 6b (MIC = 0.39 µg/mL) was twofold more active than Rifampin (0.8 µg/mL). • Compounds 6b and 6f possessed low level of cytotoxicity against Vero cells. • Molecular docking study revealed higher C-score values that supports the findings. In this work, we report a series of 4-(2,6-dimethylphenyl)thio)methyl)-2H-chromen-2-one conjugates as promising leads to treat tuberculosis. Spectroscopic and other analytical methods were used to validate the synthesised compounds. The compounds were assessed for in vitro anti-tubercular activity with the H 37 Rv strain of Mycobacterium tuberculosis. Further, cytotoxicity studies were performed using Vero cells. Most of the synthesised conjugates were effective and displayed notable activity with MIC values in the range 0.39–12.5 µg/mL.The most diligent compound 6b (MIC = 0.39 µg/mL) was twofold more active than standard anti-TB drug Rifampin (0.8 µg/mL) and was comparable to Isoniazid (0.1 µg/mL). Compound 6f also displayed exemplary activity (MIC 0.78 µg/mL). Both compounds 6b and 6f possessed low levels of cytotoxicity, Molecular docking evaluation of the synthesised conjugates and 4DQU ligand demonstrated that the synthesised conjugates had higher C-score values that further supports the obtained results. It indicates compound 6b and 6f are promising lead compounds in search of novel antitubercular drug-like molecules. [Display omitted] [ABSTRACT FROM AUTHOR]